How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,414 results for

Skin Conditions in Diabetes Mellitus

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)

hypothesis for this study is that at a dose with sufficient safety, the mean maximal glucose infusion rate (GIRmax) after single subcutaneous (SC) administration of MK-1092 in adult participants with T1DM is within an acceptable range. (Part 3) Condition or disease Intervention/treatment Phase Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus Drug: MK-1092, 4.0 nmol/kg Drug: MK-1092, 8.0 nmol/kg Drug: MK-1092, 16 nmol/kg Drug: MK-1092, 32 nmol/kg Drug: MK-1092, 64 nmol/kg Drug: Glargine 3.0 nmol/kg Drug (...) Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001) Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study

2017 Clinical Trials

62. A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabeti

, 2019 Sponsor: Novo Nordisk A/S Information provided by (Responsible Party): Novo Nordisk A/S Study Details Study Description Go to Brief Summary: This trial is conducted in Asia. The aim of this trial is to confirm the superiority of insulin degludec/liraglutide versus insulin degludec in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus after 26 weeks of treatment Condition or disease Intervention/treatment Phase Diabetes Diabetes Mellitus, Type 2 Drug: Insulin degludec (...) A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabeti A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral

2017 Clinical Trials

63. Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus

or sulfonylurea on glycaemic control after 30 weeks of treatment in subjects with type 2 diabetes. Subjects will remain on their pre-trial medication. Condition or disease Intervention/treatment Phase Diabetes Diabetes Mellitus, Type 2 Drug: Semaglutide Drug: Placebo Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 302 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant (...) Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached

2017 Clinical Trials

64. oxLDL in Diabetes Mellitus Patients and Disease Periodontal

. The aim of this study is to establish whether individuals with DM with or without chronic periodontitis have an increase in oxLDL and what is the influence of periodontal treatment in the reduction of oxLDL with consequent improvement in Diabetes Mellitus parameters. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus With Periodontal Disease Procedure: Non-surgical periodontal treatment Not Applicable Detailed Description: Periodontal disease (PD) and diabetes mellitus type 2 (...) (DM2) have the same inflammatory etiopathogenesis and demonstrate a bidirectional relationship, for DM2 affects the severity of PD, and this may contribute to the overall inflammatory burden of the individual, influencing the natural course DM2. The aim of this study is to establish whether individuals with DM with or without chronic periodontitis have an increase in oxLDL and what is the influence of periodontal treatment in the reduction of oxLDL with consequent improvement in Diabetes Mellitus

2017 Clinical Trials

65. The Association Between Diabetes Mellitus, Oral Lichen Planus and Insulin-like Growth Factors 1 and 2 (IGF1 and IGF2)

metabolism, which may be related to hormones regulating carbohydrate, insulin and insulin-like growth factors 1 and 2 (IGF-1 and IGF-2) metabolism. The hypothesis of our research is that patients with diabetes mellitus and oral lichen ruber lesions will have a disturbance of insulin-like growth factors 1 and 2 and hence a greater risk of malignant transformation, compared to patients with oral lichen ruber without diabetes and healthy patients without alterations in the oral mucosa. Condition or disease (...) , 2017 Last Update Posted: August 31, 2017 Last Verified: August 2017 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Diabetes Mellitus Lichen Planus Lichen Planus, Oral Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Lichenoid Eruptions Skin Diseases

2017 Clinical Trials

66. A Study to Compare Pharmacokinetics (PK) and Pharmacodynamics (PD) of SAR341402 to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus

A Study to Compare Pharmacokinetics (PK) and Pharmacodynamics (PD) of SAR341402 to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus A Study to Compare Pharmacokinetics (PK) and Pharmacodynamics (PD) of SAR341402 to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study (...) Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Compare Pharmacokinetics (PK) and Pharmacodynamics (PD) of SAR341402 to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov

2017 Clinical Trials

67. Glucocorticoids and Skin Healing in Diabetes (GC-SHealD)

Details Study Description Go to Brief Summary: The study aims to investigate effects of inhibiting glucocorticoid activation on skin function and wound healing in patients with type 2 diabetes. Half of patients will be given a drug to inhibit glucocorticoid activation and the other half will be given a placebo. Condition or disease Intervention/treatment Phase Diabetes Mellitus, Type 2 Drug: AZD4017 Drug: Placebo Phase 2 Detailed Description: Glucocorticoids are known to impair skin function and wound (...) information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Ana Tiganescu, PhD, University of Leeds: skin wound healing 11 beta-hydroxysteroid dehydrogenase type 1 Additional relevant MeSH terms: Layout table for MeSH terms Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Niacinamide Vitamin B Complex Vitamins Micronutrients Nutrients Growth Substances Physiological

2017 Clinical Trials

68. Predictors of Skin Temperature, Plantar Pressure and Ulceration in Diabetic Foot Patients.

is to determine which variables can be used to predict plantar pressure and skin temperature and which factors are associated with the development of foot ulcers in patients with established diagnosis of diabetic foot. The associations between skin temperature and plantar pressure will also be addressed. Condition or disease Diabetic Foot Diabetes Study Design Go to Layout table for study information Study Type : Observational [Patient Registry] Estimated Enrollment : 100 participants Observational Model (...) Predictors of Skin Temperature, Plantar Pressure and Ulceration in Diabetic Foot Patients. Predictors of Skin Temperature, Plantar Pressure and Ulceration in Diabetic Foot Patients. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2017 Clinical Trials

69. Skin Conditions in Diabetes Mellitus

Skin Conditions in Diabetes Mellitus Skin Conditions in Diabetes Mellitus Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Skin (...) Conditions in Diabetes Mellitus Skin Conditions in Diabetes Mellitus Aka: Skin Conditions in Diabetes Mellitus , Diabetic Skin Disorders II. Associated Conditions: Diabetes Mellitus related See Xanthoma diabeticorum Xanthomas suggest Bullosis Diabeticorum (rare) e on extremities (especially feet) Usually heel without scarring Diabetic Ulcer Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Skin Conditions in Diabetes Mellitus." Click

2015 FP Notebook

70. Treatment of Diabetes in Older Adults Full Text available with Trip Pro

is hospitalized. Overall diabetes management. For selected patients, the endocrinologist or diabetes care specialist and the diabetes care team are primarily responsible for diabetes care and collaborate with providers who manage the patient’s other health problems and comorbidities. This situation may occur by default if the patient has no primary care provider or if the patient is already under the care of the endocrinologist or diabetes care specialist for long-standing T1D or other endocrine conditions (...) Cognition Bone mineral density Neuropathy Fall risk AAA ultrasound Medical nutrition therapy Weight (kg)/height (m) 2 = BMI Diabetes screening (for nondiabetic persons) Diabetes management Blood pressure Diabetes self-management training Tobacco use Alcohol use Medication review Cancer screening Hearing Comorbid conditions Visual acuity Frailty/physical performance General Health Assessment General Health Tests Diabetes-Specific Health Functional status (ADLs/IADLs ) ECG Retinopathy Depression Lipid

2019 The Endocrine Society

71. Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada

Henderson MA, PhD, Mariam Naqshbandi Hayward MSc, Ellen Toth MD, FRCPC Appendices S307 Appendix 1: Diabetes Canada Diabetes Charter S308 Appendix 2: Etiologic Classification of Diabetes Mellitus S309 Appendix 3: Sample Diabetes Patient Care Flow Sheet for Adults S311 Appendix 4: Smarter Step Count Prescription S312 Appendix 5: Self-Monitoring of Blood Glucose (SMBG) Recommendation Tool for Health-Care Providers S314 Appendix 6: Types of Insulin S315 Appendix 7: Therapeutic Considerations for Renal (...) (2018) A6–A16 Carol Schwartz MD FRCSC DABO Staff Ophthalmologist, Sunnybrook Health Sciences Centre Assistant Professor, Ophthalmology University of Toronto Toronto, ON Alan Sinclair MSc MD FRCP Director, Foundation for Diabetes Research in Older People, and Aston University Birmingham, UK Marsha Werb MD FRCPC Endocrinology and Metabolism Assistant Professor, University of Toronto Toronto, ON Thomas Wolever DM PhD Professor, Department of Nutritional Sciences University of Toronto Toronto, ON Staff

2018 Diabetes Canada

72. Hyperbaric oxygen therapy for diabetic foot syndrome

Hyperbaric oxygen therapy for diabetic foot syndrome 1 Translation of Chapters 1 to 6 of the final report Hyperbare Sauerstofftherapie bei diabetischem Fußsyndrom (Version 1.1; Status: 20 April 2016). Please note: This translation is provided as a service by IQWiG to English- language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract Hyperbaric oxygen therapy for diabetic foot syndrome 1 IQWiG Reports – Commission N15-02 Extract of final (...) report N15-02 Version 1.1 Hyperbaric oxygen therapy for diabetic foot syndrome 20 April 2016 Institute für Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Hyperbaric oxygen therapy for diabetic foot syndrome Commissioning agency: Federal Joint Committee Commission awarded on: 20 February 2015 Internal Commission No.: N15-02 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

73. Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2)

) or sitagliptin (SITA) at the dose of 100 mg/day (N = 36), as a single daily dose, for 12 weeks. Condition or disease Intervention/treatment Phase Diabetes Mellitus, Type 2 Drug: Evogliptin Drug: Sitagliptin Drug: Placebo Evogliptin Drug: Placebo Sitagliptin Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 146 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider (...) Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2) Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2016 Clinical Trials

74. Gastrointestinal Manifestations of Diabetes Mellitus

Gastrointestinal Manifestations of Diabetes Mellitus Gastrointestinal Manifestations of Diabetes Mellitus Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse (...) Cancer Administration 4 Gastrointestinal Manifestations of Diabetes Mellitus Gastrointestinal Manifestations of Diabetes Mellitus Aka: Gastrointestinal Manifestations of Diabetes Mellitus , Diabetes Related Gastrointestinal Conditions II. Associated Conditions: Esophagus, Stomach and Bowel Increased with longer standing (Type I or Type II) Esophageal Reflux Mechanism: , decreased lower esophageal sphincter tone, prolonged transit time ( ) Increased association with (5-10 fold increased risk

2018 FP Notebook

75. Diabetes Mellitus Control in Hospital

Diabetes Mellitus Control in Hospital Diabetes Mellitus Control in Hospital Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Diabetes (...) Mellitus Control in Hospital Diabetes Mellitus Control in Hospital Aka: Diabetes Mellitus Control in Hospital , Inpatient Diabetes Control , Glycemic Control in Hospitalized Patients , Inpatient Glucose Management , Emergency Department Hyperglycemia Management From Related Chapters II. Complications: Uncontrolled Blood Glucose Decreased survival Increased cardiac or Worse outcomes following cerebovascular accident Increased mortality following acute Increased nosocmial and s Delayed Prolonged

2018 FP Notebook

76. Diabetes Mellitus Glucose Management

Diabetes Mellitus Glucose Management Diabetes Mellitus Glucose Management Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Diabetes (...) Mellitus Glucose Management Diabetes Mellitus Glucose Management Aka: Diabetes Mellitus Glucose Management , Blood Glucose Monitoring Goals , Blood Glucose Monitoring Schedule , Blood Glucose Monitoring , Blood Sugar Monitoring From Related Chapters II. History: Diabetes Mellitus Pharmacology 1922: Crude Extracts by Banting and Best 1940: developed 1950: s developed 1960: s off market 1970: s III. Protocol: Blood Glucose Monitoring Goals Target (>50% of readings in range) Children under age 6 Before

2018 FP Notebook

77. Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus Type 2 Diabetes Mellitus Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Type 2 Diabetes Mellitus Type 2 (...) Diabetes Mellitus Aka: Type 2 Diabetes Mellitus , Type II Diabetes Mellitus , Non-Insulin Dependent Diabetes Mellitus , NIDDM , Type II Diabetes From Related Chapters II. Epidemiology Represents 90% of all Typically occurs over age 40 years in obese patients Type II Diabetes Mellitus is rapidly increasing in the United States : 22 Million in 2014 (was 5.5 Million in 1980) More than 8 Million are estimated to be undiagnosed (27%) Over 29 Million people with Type II Diabetes represents over 9% of the U.S

2018 FP Notebook

78. Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus Type 1 Diabetes Mellitus Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Type 1 Diabetes Mellitus Type 1 (...) eyesight A blood test can show if you have diabetes. If you do, you will need to take for the rest of your life. NIH: National Institute of Diabetes and Digestive and Kidney Diseases Definition (NCI) A chronic condition characterized by minimal or absent production of insulin by the pancreas.(NICHD) Definition (MSH) A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS

2018 FP Notebook

79. Type 2 Diabetes Mellitus in Children

Type 2 Diabetes Mellitus in Children Type 2 Diabetes Mellitus in Children Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Type 2 (...) Diabetes Mellitus in Children Type 2 Diabetes Mellitus in Children Aka: Type 2 Diabetes Mellitus in Children , Pediatric Type II Diabetes Mellitus , Non-Insulin Dependent Diabetes in Children From Related Chapters II. Epidemiology One in 3 new cases of childhood in U.S. are type 2 III. Risk Factors (BMI) >85th percentile for age and gender or Weight for Height >85th percentile for age and gender or for height >120th percentile for age and gender of Type 2 Diabetes in first or second degree relative

2018 FP Notebook

80. Management of Diabetic Foot

Diabetic foot can be defined as infection, ulceration or destruction of tissues of the foot associated with neuropathy and/or peripheral arterial disease of people with diabetes mellitus (DM). 1 About 80% of non-traumatic lower limb amputations in patients with diabetes are preceded by a foot ulcer. Around 50% of patients with diabetes die within five years of developing a foot ulcer, and up to 70% die within five years after an amputation. 2 It also accounts for substantial health care resources. Thus (...) Practice Guidelines published in 2015 (available at http://www.moh. gov.my/penerbitan/mymahtas/CPG_MANUAL_MAHTAS.pdf). vManagement of Diabetic Foot (Second Edition) OBJECTIVES The objectives of the CPG are to provide evidence-based recommendations on the management of diabetic foot in the following aspects: a. assessment b. referral c. prevention d. treatment CLINICAL QUESTIONS Refer to Appendix 2. TARGET POPULATION Inclusion Criteria All patients with diabetes mellitus who are at risk or have

2018 Ministry of Health, Malaysia

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>